Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct;10(10):3986–3999. doi: 10.21037/tau-20-1117

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Andrology and Urology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Kaplan-Meier analyses for the changes of the biomarkers collectively. (A) For patients with favorable changes in all of the three markers (PSA-decline >50%, ALP-bouncing and LDH-normalization) PFS was 11 vs. 4 months (P=0.01) compared to the group of patients with a PSA-decline >50% alone; (B) for patients with favorable changes in all of the three markers (PSA-decline >50%, ALP-bouncing and LDH-normalization) OS was 20 vs. 8 months (P=0.017) compared to the group of patients with a PSA-decline >50% alone. PSA, prostate-specific antigen; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.